OTHER FUNCTIONS TAS::75 0849::TAS; THIS MODIFICATION ADDS FUNDING FOR WA'S 2 AND

为药物发现和开发项目的早期阶段提供合成支持。指定用于合成的化合物来自DCTD的NExT计划和生物评估委员会（BEC）的建议。本合同涉及的综合工作源于上述方案。为提高先导化合物的效力和药效学特性而进行的类似物合成，其核心化学成分已得到充分确认或未知，也属于合同范围。此外，合同还将用于根据需要检查选定化合物的纯度和特性。将通过最先进的分析化学方法确定所有再合成化合物和中间体的纯度和鉴别。合成的量通常从200毫克到100克不等。根据这些合同，成功的要约人可能需要通过平行合成来合成小的组合文库。合成路线的大纲，以及更常见的是，从文献中获得的详细实验程序，将可用于大多数作业。在没有可用程序的情况下，或在已公布的方法在实践中证明不可靠的情况下，可能需要开发合成方法。

Provide synthesis support for the early stages of the drug discovery and development program. The compounds assigned for the synthesis originate from the DCTD�s NExT program and the Biological Evaluation Committee (BEC) recommendations. The synthesis work involved in this contract originates from the above mentioned programs. Synthesis of analogs in order to improve the potencies and pharmacodynamic properties of lead compounds where the core chemistry is either well established or unknown also would fall within the scope of the contract. In addition, the contracts will be utilized to check the purity and identity of selected compounds as needed. The purity and identity of all resynthesized compounds and intermediates will be established by state-of-the-art analytical chemistry methods. The quantities synthesized would generally vary from 200 mg to 100 grams. Under these contracts the successful Offerors may be required to synthesize small combinatorial libraries by parallel synthesis. Outlines of synthetic routes, and more commonly, detailed experimental procedures obtained from the literature, will be available for the majority of the assignments. Development of synthetic methods may be required in those cases where no procedures are available, or when the published methods prove unreliable in practice.